title: Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization.
abstract: The purine nucleoside adenosine is present in all cells in tightly regulated concentrations. It is released under a variety of physiological and pathophysiological conditions to facilitate protection and regeneration of tissues. Adenosine acts via specific GPCRs to either stimulate cyclic AMP formation, as exemplified by Gs -protein-coupled adenosine receptors (A2A and A2B ), or inhibit AC activity, in the case of Gi/o -coupled adenosine receptors (A1 and A3 ). Recent advances in our understanding of GPCR structure have provided insights into the conformational changes that occur during receptor activation following binding of agonists to orthosteric (i.e. at the same binding site as an endogenous modulator) and allosteric regulators to allosteric sites (i.e. at a site that is topographically distinct from the endogenous modulator). Binding of drugs to allosteric sites may lead to changes in affinity or efficacy, and affords considerable potential for increased selectivity in new drug development. Herein, we provide an overview of the properties of selective allosteric regulators of the adenosine A1 and A3 receptors, focusing on the impact of receptor dimerization, mechanistic approaches to single-cell ligand-binding kinetics and the effects of A1 - and A3 -receptor allosteric modulators on in vivo pharmacology.
authors.affiliation: Cell Signalling Research Group, School of Biomedical Sciences, Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Hill
authors.forename: Lauren T
authors.initials: LT
authors.lastname: May
authors.forename: Barrie
authors.initials: B
authors.lastname: Kellam
authors.forename: Jeanette
authors.initials: J
authors.lastname: Woolard
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D006801:Humans; D008024:Ligands; D055503:Protein Multimerization; D043682:Receptor, Adenosine A1 / Q000378:metabolism*; D043684:Receptor, Adenosine A3 / Q000378:metabolism*
chemical_list: D008024:Ligands; D043682:Receptor, Adenosine A1; D043684:Receptor, Adenosine A3
keywords: GPCR; adenosine; allosterism; biased signalling; dimerization; receptor
references.citation: J Med Chem. 2003 Feb 27;46(5):794-809
references.pmid: 12593659
references.citation: Cephalalgia. 2003 May;23(4):287-92
references.pmid: 12716347
references.citation: Br J Pharmacol. 2006 Aug;148(7):927-37
references.pmid: 16847442
references.citation: Cardiovasc Res. 1997 Oct;36(1):52-9
references.pmid: 9415272
references.citation: Neoplasia. 2009 Oct;11(10):1064-73
references.pmid: 19794965
references.citation: Circ Res. 2007 Nov 26;101(11):1130-8
references.pmid: 17901362
references.citation: J Med Chem. 2011 Dec 8;54(23):8195-206
references.pmid: 22007643
references.citation: Br J Pharmacol. 2012 Mar;165(6):1659-1669
references.pmid: 22023017
references.citation: Biochem Biophys Res Commun. 2006 Dec 15;351(2):559-65
references.pmid: 17070771
references.citation: Eur J Med Chem. 2004 Oct;39(10):855-65
references.pmid: 15464619
references.citation: J Med Chem. 2008 Sep 25;51(18):5875-9
references.pmid: 18729349
references.citation: Int J Mol Med. 2011 Nov;28(5):727-31
references.pmid: 21887476
references.citation: EMBO Rep. 2013 Aug;14(8):726-32
references.pmid: 23817552
references.citation: Trends Pharmacol Sci. 1996 Aug;17(8):280-3
references.pmid: 8810873
references.citation: Neuropharmacology. 2011 Jan;60(1):24-35
references.pmid: 20637785
references.citation: Mol Pharmacol. 2001 Nov;60(5):1057-63
references.pmid: 11641434
references.citation: Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1875-82
references.pmid: 16679400
references.citation: Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6541-6
references.pmid: 9177254
references.citation: Nat Neurosci. 2010 Jul;13(7):883-8
references.pmid: 20512135
references.citation: Science. 2012 Jul 13;337(6091):232-6
references.pmid: 22798613
references.citation: Science. 2011 Apr 15;332(6027):322-7
references.pmid: 21393508
references.citation: Int J Oncol. 2008 Aug;33(2):287-95
references.pmid: 18636149
references.citation: Biochem Pharmacol. 2011 Sep 15;82(6):658-68
references.pmid: 21718691
references.citation: Mol Pharmacol. 1996 Dec;50(6):1635-42
references.pmid: 8967987
references.citation: Drug Discov Today. 2012 Apr;17(7-8):359-66
references.pmid: 22033198
references.citation: Mol Pharmacol. 2006 May;69(5):1652-61
references.pmid: 16467191
references.citation: J Neural Transm (Vienna). 2010 Nov;117(11):1269-77
references.pmid: 20809069
references.citation: J Biol Chem. 2004 Jan 2;279(1):686-91
references.pmid: 14559905
references.citation: FEBS Lett. 1996 Feb 19;380(3):219-23
references.pmid: 8601428
references.citation: Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2693-8
references.pmid: 20133736
references.citation: J Am Soc Nephrol. 2004 Jan;15(1):102-11
references.pmid: 14694162
references.citation: J Med Chem. 2009 Feb 26;52(4):926-31
references.pmid: 19161279
references.citation: Biochem Pharmacol. 2012 Jul 1;84(1):76-87
references.pmid: 22449615
references.citation: Purinergic Signal. 2013 Sep;9(3):433-49
references.pmid: 23657626
references.citation: Mol Pharmacol. 2002 Jul;62(1):81-9
references.pmid: 12065758
references.citation: J Med Chem. 2006 Jun 1;49(11):3354-61
references.pmid: 16722654
references.citation: Nature. 2011 Sep 28;477(7366):611-5
references.pmid: 21956331
references.citation: Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11406-11
references.pmid: 13679574
references.citation: J Neurochem. 2008 Oct;107(1):161-70
references.pmid: 18680557
references.citation: J Pharmacol Exp Ther. 2004 Mar;308(3):1062-72
references.pmid: 14711931
references.citation: Mol Pharmacol. 2003 Dec;64(6):1357-69
references.pmid: 14645666
references.citation: Clin Res Cardiol. 2012 Jul;101(7):585-91
references.pmid: 22370739
references.citation: Trends Mol Med. 2011 Mar;17(3):126-39
references.pmid: 21183406
references.citation: Nature. 2011 Jul 19;477(7366):549-55
references.pmid: 21772288
references.citation: Science. 2008 Nov 21;322(5905):1211-7
references.pmid: 18832607
references.citation: Bioorg Med Chem. 2008 Feb 1;16(3):1319-27
references.pmid: 17980606
references.citation: Br J Pharmacol. 2013 Dec;170(8):1459-581
references.pmid: 24517644
references.citation: Purinergic Signal. 2013 Mar;9(1):91-100
references.pmid: 23054444
references.citation: Mol Pharmacol. 2010 Sep;78(3):444-55
references.pmid: 20547736
references.citation: Epilepsia. 2012 Nov;53(11):1978-86
references.pmid: 23106524
references.citation: Biochim Biophys Acta. 2008 Dec;1783(12):2262-8
references.pmid: 18691614
references.citation: J Pharmacol Exp Ther. 1993 Aug;266(2):611-7
references.pmid: 8355194
references.citation: Purinergic Signal. 2012 Feb;8(Suppl 1):91-9
references.pmid: 22081230
references.citation: Biochem Biophys Res Commun. 1975 Jun 16;64(4):1160-8
references.pmid: 1137592
references.citation: Cardiovasc Res. 2002 Jan;53(1):147-55
references.pmid: 11744023
references.citation: Science. 2010 Nov 19;330(6007):1091-5
references.pmid: 21097933
references.citation: Am J Physiol Renal Physiol. 2012 Sep;303(5):F721-32
references.pmid: 22759398
references.citation: Prog Mol Biol Transl Sci. 2013;117:143-62
references.pmid: 23663968
references.citation: Bioorg Med Chem. 2006 Apr 1;14(7):2358-65
references.pmid: 16314104
references.citation: Brain Res. 1993 Aug 13;619(1-2):131-6
references.pmid: 8374770
references.citation: Am J Physiol Renal Physiol. 2000 Mar;278(3):F380-7
references.pmid: 10710542
references.citation: Clin Cancer Res. 2004 Jul 1;10(13):4472-9
references.pmid: 15240539
references.citation: Annu Rev Pharmacol Toxicol. 2007;47:1-51
references.pmid: 17009927
references.citation: Biochim Biophys Acta. 2011 May;1808(5):1290-308
references.pmid: 21185259
references.citation: Structure. 2012 Dec 5;20(12):2161-73
references.pmid: 23142347
references.citation: Methods Mol Biol. 2009;552:39-50
references.pmid: 19513640
references.citation: J Biol Chem. 2009 Jul 17;284(29):19533-43
references.pmid: 19451648
references.citation: Nat Chem Biol. 2009 Sep;5(9):688-95
references.pmid: 19648932
references.citation: Mol Pain. 2010 Apr 14;6:20
references.pmid: 20398264
references.citation: J Cell Physiol. 2011 Sep;226(9):2438-47
references.pmid: 21660967
references.citation: Exp Neurol. 2003 Sep;183(1):188-96
references.pmid: 12957503
references.citation: Mol Pharmacol. 2003 May;63(5):1021-31
references.pmid: 12695530
references.citation: J Med Chem. 1974 Jun;17(6):624-30
references.pmid: 4829942
references.citation: Hypertension. 2001 Apr;37(4):1095-100
references.pmid: 11304509
references.citation: Mol Pharmacol. 2004 Apr;65(4):986-98
references.pmid: 15044629
references.citation: Science. 2006 Dec 15;314(5806):1792-5
references.pmid: 17170310
references.citation: Mol Pharmacol. 2010 Sep;78(3):511-23
references.pmid: 20571079
references.citation: Br J Pharmacol. 2004 Nov;143(6):705-14
references.pmid: 15302686
references.citation: Drug Discov Today Technol. 2013 Summer;10(2):e285-96
references.pmid: 24050280
references.citation: Nature. 2012 Dec 6;492(7427):57
references.pmid: 23222609
references.citation: FASEB J. 2013 Mar;27(3):1048-61
references.pmid: 23193172
references.citation: Br J Pharmacol. 2008 Mar;153(6):1331-40
references.pmid: 18157164
references.citation: Neuropsychopharmacology. 2011 Jan;36(1):358
references.pmid: 21116251
references.citation: J Pharmacol Exp Ther. 2012 Jan;340(1):210-7
references.pmid: 22011434
references.citation: Biochim Biophys Acta. 2011 May;1808(5):1309-18
references.pmid: 20599682
references.citation: Purinergic Signal. 2012 Sep;8(3):587-98
references.pmid: 22528684
references.citation: Nat Chem Biol. 2011 Jul 24;7(9):624-30
references.pmid: 21785426
references.citation: J Biol Chem. 2010 May 28;285(22):16723-38
references.pmid: 20304928
references.citation: J Med Chem. 1999 Sep 9;42(18):3629-35
references.pmid: 10479294
references.citation: FASEB J. 2011 Oct;25(10):3465-76
references.pmid: 21715680
references.citation: Mol Pharmacol. 1995 Aug;48(2):362-78
references.pmid: 7651370
references.citation: Biochem Pharmacol. 1991 Jul 5;42(2):199-205
references.pmid: 1859442
references.citation: Mol Pharmacol. 2010 Apr;77(4):678-86
references.pmid: 20086038
references.citation: Biochem Pharmacol. 1991 Oct 24;42(10):1927-32
references.pmid: 1741770
references.citation: J Pharmacol Exp Ther. 2006 Dec;319(3):1200-10
references.pmid: 16985166
references.citation: J Biol Chem. 2000 Feb 11;275(6):4429-34
references.pmid: 10660615
references.citation: Clin Cancer Res. 2004 Sep 1;10(17):5895-901
references.pmid: 15355922
references.citation: Br J Pharmacol. 2008 Mar;153(6):1087-9
references.pmid: 18264119
references.citation: Handb Exp Pharmacol. 2009;(193):1-24
references.pmid: 19639277
references.citation: Mol Pharmacol. 1990 Dec;38(6):950-8
references.pmid: 2250667
references.citation: J Med Chem. 2009 Jul 23;52(14):4543-7
references.pmid: 19514747
references.citation: J Biol Chem. 2009 Sep 25;284(39):26732-41
references.pmid: 19542234
references.citation: Pharmacol Rev. 2011 Mar;63(1):1-34
references.pmid: 21303899
references.citation: Ann Thorac Surg. 1998 Aug;66(2):382-7
references.pmid: 9725373
references.citation: Cell Signal. 2013 Apr;25(4):736-42
references.pmid: 23291003
references.citation: Pharmacol Rev. 2010 Dec;62(4):701-25
references.pmid: 21079041
references.citation: J Neurochem. 2010 Aug;114(4):972-80
references.pmid: 20477947
references.citation: Biochem Pharmacol. 1997 Mar 21;53(6):795-800
references.pmid: 9113100
references.citation: Mol Pharmacol. 1990 Dec;38(6):939-49
references.pmid: 2174510
references.citation: Br J Pharmacol. 1993 Oct;110(2):619-26
references.pmid: 7902176
references.citation: Trends Pharmacol Sci. 2009 Sep;30(9):460-9
references.pmid: 19729207
references.citation: Pharmacol Rev. 2002 Jun;54(2):323-74
references.pmid: 12037145
references.citation: Adv Pharmacol. 2011;61:187-220
references.pmid: 21586360
references.citation: FASEB J. 2012 Feb;26(2):604-16
references.pmid: 22031716